A compound having the formula wherein: n is an integer from 0 to 2; A is XNH- or R 5 XN-, where R 5 is selected from the group consisting of hydroxy, C 1 -C 6 alkyl, C 1 -C 4 alkoxycarbonyl, and benzyl; and where X is optionally-substituted aryl(C 1 -C 4 alkyl); A' is R 5' X'N-, where R 5' and X' are taken together with the attached nitrogen atom to form a piperidinyl optionally substituted at the 4-position with hydroxy, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 4 alkoxy, (C 1 -C 4 alkoxy)carbonyl, (hydroxy(C 1 -C 4 alkoxy))-(C 1 -C 4 alkyl), R 7 R 8 N-, R 7 R 8 N-(C 1 -C 4 alkyl), phenyl, phenyl(C 1 -C 4 alkyl), optionally-substituted phenyl(C 1 -C 4 alkyl), furyl(C 1 -C 4 alkyl), pyridinyl(C 1 -C 4 alkyl), thienyl(C 1 -C 4 alkyl), or piperidin-1-yl(C 1 -C 4 alkyl); R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is 4-substituted oxazolidin-2-on-3-yl; R 4 is optionally-substituted arylethen-1-yl; R 7 is hydrogen or C 1 -C 6 alkyl; R 8 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, optionally-substituted aryl, or optionally-substituted aryl(C 1 -C 4 alkyl); or R 7 and R 8 are taken together with the attached nitrogen atom to form an heterocycle selected from the group consisting of pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and homopiperazinyl; where said piperazinyl or homopiperazinyl is optionally N -substitued with R 12; R 12 is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 4 alkoxycarbonyl, optionally-substituted aryloxycarbonyl, optionally-substituted aryl(C 1 -C 4 alkyl), and optionally-substituted aryloyl; and hydrates, solvates and pharmaceutically acceptable acid addition salts thereof. n is an integer from 0 to 2; A is XNH- or R 5 XN-, where R 5 is selected from the group consisting of hydroxy, C 1 -C 6 alkyl, C 1 -C 4 alkoxycarbonyl, and benzyl; and where X is optionally-substituted aryl(C 1 -C 4 alkyl); A' is R 5' X'N-, where R 5' and X' are taken together with the attached nitrogen atom to form a piperidinyl optionally substituted at the 4-position with hydroxy, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 4 alkoxy, (C 1 -C 4 alkoxy)carbonyl, (hydroxy(C 1 -C 4 alkoxy))-(C 1 -C 4 alkyl), R 7 R 8 N-, R 7 R 8 N-(C 1 -C 4 alkyl), phenyl, phenyl(C 1 -C 4 alkyl), optionally-substituted phenyl(C 1 -C 4 alkyl), furyl(C 1 -C 4 alkyl), pyridinyl(C 1 -C 4 alkyl), thienyl(C 1 -C 4 alkyl), or piperidin-1-yl(C 1 -C 4 alkyl); R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is 4-substituted oxazolidin-2-on-3-yl; R 4 is optionally-substituted arylethen-1-yl; R 7 is hydrogen or C 1 -C 6 alkyl; R 8 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, optionally-substituted aryl, or optionally-substituted aryl(C 1 -C 4 alkyl); or R 7 and R 8 are taken together with the attached nitrogen atom to form an heterocycle selected from the group consisting of pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and homopiperazinyl; where said piperazinyl or homopiperazinyl is optionally N -substitued with R 12; R 12 is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 4 alkoxycarbonyl, optionally-substituted aryloxycarbonyl, optionally-substituted aryl(C 1 -C 4 alkyl), and optionally-substituted aryloyl; and hydrates, solvates and pharmaceutically acceptable acid addition salts thereof.